Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells 83,817 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 83,817 shares of Invivyd stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $0.54, for a total transaction of $45,261.18. Following the sale, the director now directly owns 3,340,520 shares of the company’s stock, valued at approximately $1,803,880.80. This trade represents a 2.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The stock was sold at an average price of $0.45, for a total transaction of $34,099.20.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The stock was sold at an average price of $0.42, for a total transaction of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Trading Up 4.0 %

Shares of NASDAQ:IVVD opened at $0.53 on Friday. The firm has a market cap of $63.44 million, a price-to-earnings ratio of -0.27 and a beta of 0.53. The stock’s 50-day moving average price is $0.74 and its two-hundred day moving average price is $0.99. Invivyd, Inc. has a 12-month low of $0.40 and a 12-month high of $5.20.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IVVD. Morgan Stanley lowered their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. HC Wainwright dropped their price target on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Invivyd in a research report on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $7.89.

Institutional Trading of Invivyd

Institutional investors and hedge funds have recently bought and sold shares of the business. Duquesne Family Office LLC purchased a new stake in shares of Invivyd in the second quarter worth about $629,000. Acadian Asset Management LLC raised its holdings in shares of Invivyd by 232.0% during the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock valued at $745,000 after buying an additional 474,301 shares during the period. Cornercap Investment Counsel Inc. acquired a new position in Invivyd during the 2nd quarter worth approximately $86,000. Cubist Systematic Strategies LLC boosted its holdings in Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after acquiring an additional 53,499 shares during the period. Finally, SG Americas Securities LLC grew its position in Invivyd by 198.6% in the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after acquiring an additional 25,201 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.